---
title: "《大行》瑞银对医疗健康股投资评级及目标价 (表)"
description: "瑞银发布研究报告，列出医疗健康股的投资评级及目标价。恒瑞医药评级为买入，目标价从 96.9 元上调至 98.3 元；翰森制药评级为买入，目标价从 48.2 元上调至 51.5 元；中生制药评级为买入，目标价为 12.2 元；三生制药评级为买入，目标价为 41 元；石药集团评级为中性，目标价从 10 元上调至 10.9 元；先声药业评级为买入，目标价为 16.3 元；联邦制药评级为买入，目标价为 1"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/277163725.md"
published_at: "2026-02-27T07:48:10.000Z"
---

# 《大行》瑞银对医疗健康股投资评级及目标价 (表)

> 瑞银发布研究报告，列出医疗健康股的投资评级及目标价。恒瑞医药评级为买入，目标价从 96.9 元上调至 98.3 元；翰森制药评级为买入，目标价从 48.2 元上调至 51.5 元；中生制药评级为买入，目标价为 12.2 元；三生制药评级为买入，目标价为 41 元；石药集团评级为中性，目标价从 10 元上调至 10.9 元；先声药业评级为买入，目标价为 16.3 元；联邦制药评级为买入，目标价为 18.9 元。

瑞银发表研究报告，对医疗健康股投资评级及目标价表列如下：

股份 | 投资评级 | 目标价 (港元)

恒瑞医药 (01276.HK) | 买入 | 96.9 元 → 98.3 元

翰森制药 (03692.HK) | 买入 | 48.2 元 → 51.5 元

中生制药 (01177.HK) | 买入 | 12.2 元

三生制药 (01530.HK) | 买入 | 41 元

石药集团 (01093.HK) | 中性 | 10 元 → 10.9 元

先声药业 (02096.HK) | 买入 | 16.3 元

联邦制药 (03933.HK) | 买入 | 18.9 元

### Related Stocks

- [159837.CN - 易方达中证生物科技主题ETF](https://longbridge.com/zh-CN/quote/159837.CN.md)
- [159849.CN - 招商中证生物科技主题ETF](https://longbridge.com/zh-CN/quote/159849.CN.md)
- [159316.CN - 易方达恒生港股通创新药ETF](https://longbridge.com/zh-CN/quote/159316.CN.md)
- [516930.CN - 生物科技ETF基金](https://longbridge.com/zh-CN/quote/516930.CN.md)
- [520880.CN - 华宝恒生港股通创新药精选ETF](https://longbridge.com/zh-CN/quote/520880.CN.md)
- [300765.CN - 新诺威](https://longbridge.com/zh-CN/quote/300765.CN.md)
- [516610.CN - 医服ETF](https://longbridge.com/zh-CN/quote/516610.CN.md)
- [520690.CN - 博时恒生港股通创新药精选ETF](https://longbridge.com/zh-CN/quote/520690.CN.md)
- [588250.CN - 鹏华上证科创板生物医药ETF](https://longbridge.com/zh-CN/quote/588250.CN.md)
- [589720.CN - 国泰上证科创板创新药ETF](https://longbridge.com/zh-CN/quote/589720.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| TUL Roxithromycin Capsules Gain China Consistency Evaluation Approval | The United Laboratories International Holdings Limited (TUL) announced that its subsidiary has received approval from th | [Link](https://longbridge.com/zh-CN/news/275299526.md) |
| CMB International Securities Reaffirms Their Buy Rating on 3SBio (TRSBF) | CMB International Securities analyst Jill Wu has reaffirmed a Buy rating on 3SBio (TRSBF) with a price target of HK$37.4 | [Link](https://longbridge.com/zh-CN/news/274092955.md) |
| Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | [Link](https://longbridge.com/zh-CN/news/276822785.md) |
| China Medical System Gets China Acceptance for Atopic Dermatitis Drug | China Medical System Gets China Acceptance for Atopic Dermatitis Drug | [Link](https://longbridge.com/zh-CN/news/276718382.md) |
| CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab | CStone Pharmaceuticals has received UK approval for its lung cancer drug, sugemalimab, as a monotherapy for adult patien | [Link](https://longbridge.com/zh-CN/news/276549711.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。